Literature DB >> 26923195

Targeting ROR1 inhibits the self-renewal and invasive ability of glioblastoma stem cells.

Eun-Hwa Jung1, Han-Na Lee1, Gi-Yeon Han1, Min-Jung Kim1,2, Chan-Wha Kim1.   

Abstract

Glioblastoma is the most malignant of brain tumours and is difficult to cure because of interruption of drug delivery by the blood-brain barrier system, its high metastatic capacity and the existence of cancer stem cells (CSCs). Although CSCs are present as a small population in malignant tumours, CSCs have been studied as they are responsible for causing recurrence, metastasis and resistance to chemotherapy and radiotherapy for cancer. CSCs have self-renewal characteristics like normal stem cells. The aim of this study was to investigate whether receptor tyrosine kinase-like orphan receptor 1 (ROR1) is involved in stem cell maintenance and malignant properties in human glioblastoma. Knockdown of ROR1 caused reduction of stemness and sphere formation capacity. Moreover, down-regulation of ROR1 suppressed the expression of epithelial-mesenchymal transition-related genes and the tumour migratory and invasive abilities. The results of this study indicate that targeting ROR1 can induce differentiation of CSCs and inhibit metastasis in glioblastoma. In addition, ROR1 may be used as a potential marker for glioblastoma stem cells as well as a potential target for glioblastoma stem cell therapy.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  ROR1; glioblastoma stem cells; invasion; migration; stemness

Mesh:

Substances:

Year:  2016        PMID: 26923195     DOI: 10.1002/cbf.3172

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  10 in total

1.  Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Authors:  Michael Y Choi; George F Widhopf; Emanuela M Ghia; Reilly L Kidwell; Md Kamrul Hasan; Jian Yu; Laura Z Rassenti; Liguang Chen; Yun Chen; Emily Pittman; Minya Pu; Karen Messer; Charles E Prussak; Januario E Castro; Catriona Jamieson; Thomas J Kipps
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

2.  An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors.

Authors:  Satyen Harish Gohil; Solange Rosa Paredes-Moscosso; Micaela Harrasser; Marzia Vezzalini; Aldo Scarpa; Emma Morris; Andrew M Davidoff; Claudio Sorio; Amit Chunilal Nathwani; Marco Della Peruta
Journal:  Oncoimmunology       Date:  2017-05-17       Impact factor: 8.110

3.  The ginsenoside metabolite compound K inhibits growth, migration and stemness of glioblastoma cells.

Authors:  Sanghun Lee; Min Cheol Kwon; Jun-Pil Jang; Jae Kyung Sohng; Hye Jin Jung
Journal:  Int J Oncol       Date:  2017-06-23       Impact factor: 5.650

4.  Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.

Authors:  C E Henry; C Emmanuel; N Lambie; C Loo; B Kan; C J Kennedy; A de Fazio; N F Hacker; C E Ford
Journal:  Transl Oncol       Date:  2017-03-23       Impact factor: 4.243

5.  ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells.

Authors:  Metin Cetin; Gorkem Odabas; Leon R Douglas; Patrick J Duriez; Pelin Balcik-Ercin; Irem Yalim-Camci; Abdulkadir Emre Sayan; Tamer Yagci
Journal:  Cells       Date:  2019-03-02       Impact factor: 6.600

6.  ROR1 regulates chemoresistance in Breast Cancer via modulation of drug efflux pump ABCB1.

Authors:  Norman Fultang; Abhinav Illendula; Jianhuang Lin; Manoj K Pandey; Zachary Klase; Bela Peethambaran
Journal:  Sci Rep       Date:  2020-02-04       Impact factor: 4.379

7.  ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.

Authors:  Rui Li; Tianfeng Liu; Juanjuan Shi; Wenqing Luan; Xuan Wei; Jiangtao Yu; Hongluan Mao; Peishu Liu
Journal:  J Transl Med       Date:  2019-12-26       Impact factor: 5.531

Review 8.  The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention.

Authors:  Kerstin Menck; Saskia Heinrichs; Cornelia Baden; Annalen Bleckmann
Journal:  Cells       Date:  2021-01-12       Impact factor: 6.600

9.  In-Silico Drug discovery approach targeting receptor tyrosine kinase-like orphan receptor 1 for cancer treatment.

Authors:  Onkar Nath; Archana Singh; Indrakant K Singh
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

10.  Do patients with oral squamous cell carcinoma express receptor tyrosine kinase-like orphan receptor 1? Results of an observational study.

Authors:  Swati Nema; Shreenivas Kallianpur; Ashok Kumar; Rajeev Nema; Supriya Vishwakarma; Sandeep Kumar Nema
Journal:  J Oral Maxillofac Pathol       Date:  2021-05-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.